Free Trial

ViewRay (VRAY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
108.50 million shs
Average Volume
7.51 million shs
Market Capitalization
$4.59 million
P/E Ratio
Dividend Yield
Price Target
VRAY stock logo

About ViewRay Stock (NASDAQ:VRAY)

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.

VRAY Stock News Headlines

ViewRay Inc (VRAYQ) Earnings Dates & Reports
VRAY Jan 2025 2.000 call
VRAY Jan 2025 0.500 put
VRAY Jan 2025 0.500 call
VRAY Jan 2025 3.000 put
ViewRay Inc VRAYQ
NUBURU Appoints Brian Knaley as new CEO
ViewRay Inc (6L9.BE)
Why ViewRay Stock Hit A New 52-Week Low Today
Why Is ViewRay (VRAY) Stock Down 69% Today?
ViewRay® Files Voluntary Chapter 11 Petitions
Viewray (VRAY) Receives a Hold from Stifel Nicolaus
See More Headlines
Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Electromedical equipment
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$105.86 million
Book Value
$0.45 per share


Free Float
Market Cap
$4.59 million

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Scott William DrakeMr. Scott William Drake (Age 55)
    Pres, CEO & Director
    Comp: $1.8M
  • Mr. Robert S. McCormack J.D. (Age 56)
    Chief Legal Officer
    Comp: $692.36k
  • Dr. James F. Dempsey Ph.D. (Age 52)
    Founder & Chief Scientific Officer
  • Mr. William P. Burke (Age 54)
    Exec. VP & CFO
  • Drew Hill
    Sr. VP of Operations & Devel.
  • Matt Harrison
    Director of Investor Relations
  • Karen Hackstaff
    VP of Marketing
  • Mr. Robert Michael Fuchs (Age 56)
    Chief HR Officer
  • Dr. Martin Fuss M.D.
    Ph.D., Chief Medical Officer
  • Mr. Paul Ziegler Jr. (Age 49)
    J.D., Exec. VP & Chief Commercial Officer

VRAY Stock Analysis - Frequently Asked Questions

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) issued its earnings results on Monday, February, 27th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business earned $34.70 million during the quarter, compared to analysts' expectations of $34.65 million. ViewRay had a negative trailing twelve-month return on equity of 120.48% and a negative net margin of 104.30%. ViewRay's revenue was up 70.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.16) earnings per share.

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

ViewRay (VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Does ViewRay have any subsidiaries?
The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..
Read More
This page (NASDAQ:VRAY) was last updated on 6/12/2024 by Staff

From Our Partners